



Aarey

DRUGS & PHARMACEUTICALS LTD.

**MANUFACTURERS OF BULK DRUGS &
DEALERS OF CHEMICAL & SOLVENTS**

GST No. : 27AAACA5253A1Z9
CIN No. : L99999MH1990PLC056538

HEAD OFFICE : 1227, HUBTOWN SOLARIS, N.S. PHADKE MARG, OPP, TELLI GALLI, ANDHERI - (E), MUMBAI - 400 069 INDIA . TEL. : (022) 62872900/2999 E-mail : info@aareydrugs.com
REGD. OFFICE & FACTORY : E-34, M.I.D.C.TARAPUR, BOISAR, DIST.: PALGHAR - 401 506 TEL. : (02525) 622165 E-mail : works@aareydrugs.com Web : www.aareydrugs.com

Date: 13th August, 2022

To,

BSE Limited The Manager, Corporate Service Department P.J. Towers, Dalal Street, Mumbai- 400 001 Scrip Code: 524412	National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex, Bandra (E), Mumbai – 400051 NSE Symbol: AAREYDRUGS
--	---

Sub: Outcome of Board Meeting held on today i.e 13th August, 2022

Dear Sir/Madam,

This is to inform you that the Board of Directors of the Company at its Meeting held today i.e. 13th August, 2022 have passed the following resolution.

1. The Board of Directors of the Company has considered and approved the Unaudited Financial Results for the quarter ended 30th June, 2022 along with the Limited Review Report, MD/CFO certification.

The meeting was started at 03:00p.m. and was concluded at 04:00 p.m

Kindly take the same on record.

Thanking you,

Yours Faithfully,

For AAREY DRUGS & PHARMACEUTICALS LIMITED


Mihir R Ghatalia
Managing Director
DIN: 00581005





Aarey

DRUGS & PHARMACEUTICALS LTD.

**MANUFACTURERS OF BULK DRUGS &
DEALERS OF CHEMICAL & SOLVENTS**

GST No. : 27AAACA5253A1Z9
CIN No. : L99999MH1990PLC056538

HEAD OFFICE : 1227, HUBTOWN SOLARIS, N.S. PHADKE MARG, OPP, TELLI GALLI, ANDHERI - (E), MUMBAI - 400 069 INDIA . TEL. : (022) 62872900/2999 E-mail : info@aareydrugs.com
REGD. OFFICE & FACTORY : E-34, M.I.D.C,TARAPUR, BOISAR, DIST.: PALGHAR - 401 506 TEL. : (02525) 622165 E-mail : works@aareydrugs.com Web : www.aareydrugs.com

Date: 13th August, 2022

BSE Limited The Manager, Corporate Service Department P.J. Towers, Dalal Street, Mumbai- 400 001 Scrip Code: 524412	National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex, Bandra (E), Mumbai – 400051 NSE Symbol: AAREYDRUGS
--	---

Sub: Unaudited Financial Results for the Quarter ended 30th June, 2022.

Dear Sir/Madam,

Pursuant to the Listing agreement we are enclosing herewith the Unaudited Financial Results for the quarter ended 30th June, 2022 with Limited Review Report.

Please take on record of the same and oblige.

Thanking you,

Yours Faithfully,

For Aarey Drugs & Pharmaceuticals Ltd


Mihir R Ghatalia
Managing Director
DIN: 00581005



Encl.: a/a

AAREY DRUGS & PHARMACEUTICALS LTD

CIN: L99999MH1990PLC056538

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER ENDED 30TH JUNE, 2022

Particulars	Quarter ended			Year Ended
	30.06.2022	31.03.2022	30.06.2021	31.03.2022
	Unaudited	Audited	Unaudited	Audited
Revenue from Operations	11,734.09	12,024.61	9,751.78	49,268.00
Other Income	235.42	113.45	67.08	274.76
TOTAL INCOME	11,969.51	12,138.06	9,818.86	49,542.75
EXPENSES				
Cost of Materials Consumed	11,667.35	11,545.29	8,452.69	46,728.82
Changes in Inventories of Finished goods, Work in progress and Stock in trade	6.66	-80.73	837.56	477.67
Employee Benefit Expenses	16.25	41.22	10.85	97.50
General Administrative Expense	17.21	41.84	17.47	94.80
Selling and Distribution Expense	17.82	50.68	111.37	391.51
Depreciation and Amortization Expense (incl. reversal)	40.65	58.83	40.00	198.83
Finance Cost	54.77	43.02	47.09	200.01
Other Expenses	68.78	240.21	28.97	350.90
TOTAL EXPENSES	11,889.50	11,940.36	9,546.00	48,540.05
Profit Before Exceptional Items and Tax	80.01	197.69	272.86	1,002.72
Exceptional Items	-	-	-	-
Profit / (Loss) Before Tax	80.01	197.69	272.86	1,002.72
Tax Expenses				
a) Current Tax	-	185.70	22.00	260.70
b) Deferred Tax	-	-10.78	-	-10.78
c) Short/(excess) provision of earlier years		98.31		98.31
Profit / (Loss) for the period from continuing operations	80.01	-75.54	250.86	654.49
Profit/(loss) from discontinued operations	-	-	-	-
Tax expense of discontinued operations	-	-	-	-
Profit/(loss) from Discontinued operations (after tax)	-	-	-	-
Profit/(loss) for the period	80.01	-75.54	250.86	654.50
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income for the year	80.01	-75.54	250.86	654.49
Earnings per equity share : (of Rs. 10/- each) (for the period/year): *				
a) Basic EPS (Rs.)	0.32	-0.30	1.07	2.72
b) Diluted EPS (Rs.)	0.32	-0.30	1.07	2.72




Number of Shares	25,384,684	25,384,684	23,384,684	25,384,684
Percentage of Shareholding	100%	100%	100%	100%
Paid-up Equity Share Capital (FV of Rs. 10/- each) (incl. forfeited shares)	2,538.47	2,538.47	2,338.47	2,538.47

*Not Annualised

1. Status of Investor Complaints (Nos) : Opening as on 01.07.2022 - Nil ; Received During the Quarter - 0 ; Disposed Off During the Quarter - 0 ; Closing Balance as on 30.06.2022 - Nil.
2. The Figures of the previous year / period have been regrouped wherever necessary.

Place:- Mumbai
Date:- 13/08/2022

By order of Board of Directors
For Aarey Drugs and Pharmaceuticals Limited
Mihir Ghatalia (Managing Director)
DIN:00581005





Independent Auditor's Review Report on the Quarterly Unaudited Financial Results of the Company pursuant to the Regulation 52 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended.

To,
The Board of Directors
Aarey Drugs and Pharmaceuticals Limited

1. We have reviewed the accompanying statement of unaudited financial results of **Aarey Drugs and Pharmaceuticals Limited** ("the Company") for the quarter ended June 30th, 2022 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, read with Circular No. SEBI/HO/DDHS/CIR/2021/0000000638 dated 14th October 2021 ("the 'Circular'").
2. This Statement which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind-AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 - "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, read with the Circular including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Motilal & Associates LLP
(Formerly Known As Motilal & Associates)
Chartered Accountants
ICAI FRN: 106584W/W100751

CA Motilal H. Jain
Partner
Mem. No.: 036811



Place: Mumbai
Date: 13th August, 2022

UDIN: 22036811AOYYGL3942

Certificate of Managing Director (MD)

I, Mihir R. Ghatalia, Managing Director (MD) of Aarey Drugs & Pharmaceuticals Ltd., certify;

- 1) That I have reviewed the Unaudited Financial Statements for the quarter ended 30th June, 2022 and to the best of my knowledge and belief:
 - a) These financial results do not contain any materially untrue statement or omit any material fact nor contain statement that might be misleading, and
 - b) These financial statements present a true and fair view of the Company's affairs and are in compliance with the applicable laws and regulations.
- 2) That there are to the best of my knowledge and belief, no transactions entered into by the company during the quarter, which are fraudulent, illegal or violative of the Company's Code of Conduct.
- 3) That I accept responsibility for establishing and maintaining internal controls, I have evaluated the effectiveness of the internal control systems of the Company and I have disclosed to the auditors and the Audit Committee, deficiencies in the design or operation of internal controls, if any, of which I am aware and the steps that I have taken to rectify the identified deficiencies.



Mihir R. Ghatalia

MD


Date: 13/08/2022

Place: Mumbai

Certificate of Chief Financial Officer (CFO)

I, Mira R. Ghatalia, Chief Financial Officer (CFO) of Aarey Drugs & Pharmaceuticals Ltd., certify;

- 1) That I have reviewed the Unaudited Financial Statements for the quarter ended 30th June, 2022 and to the best of my knowledge and belief:
 - a) These financial results do not contain any materially untrue statement or omit any material fact nor contain statement that might be misleading, and
 - b) These financial statements present a true and fair view of the Company's affairs and are in compliance with the applicable laws and regulations.
- 2) That there are to the best of my knowledge and belief, no transactions entered into by the company during the quarter, which are fraudulent, illegal or violative of the Company's Code of Conduct.
- 3) That I accept responsibility for establishing and maintaining internal controls, I have evaluated the effectiveness of the internal control systems of the Company and I have disclosed to the auditors and the Audit Committee, deficiencies in the design or operation of internal controls, if any, of which I am aware and the steps that I have taken to rectify the identified deficiencies.



Mira M.. Ghatalia

CFO

Date:13/08/2022

Place: Mumbai